Oxidative stress plays a role in the pathogenesis and progression of chronic obstructive
pulmonary disease (COPD). Oxidants cause structural changes in essential components of …

We reported a 24· 5% lower annualised rate of exacerbation of chronic obstructive
pulmonary disease (COPD) with carbocisteine treatment in a 1-year placebo-controlled …

Patients with Chronic Obstructive Pulmonary Disease (COPD) periodically experience acute
exacerbation (AECOPD). Carbocysteine represents a valid add on therapy in COPD by …

The importance of the underlying local and systemic oxidative stress and inflammation in
chronic obstructive pulmonary disease (COPD) has long been established. In view of the …

Mucolytics are potentially useful for the management of chronic obstructive pulmonary
disease (COPD), although there is conflicting advice on their use in different guideline …

BACKGROUND: The failure of mucus clearance in bronchiectasis can be improved by chest
physiotherapy or/and mucoactive agents. AIM: To assess the effects of long-term use of …

Background To date there are no head-to-head studies comparing different
mucolytic/antioxidant agents. Considering the inconsistent evidence resulting from the …

A prospective, randomized controlled, double-blind, controlled trial was performed to
examine the effects of carbocisteine on the frequency of common colds and exacerbations in …

Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality
and morbidity worldwide, charcterised by persistent airflow limitation, mucus hypersecretion …

ABSTRACT Introduction: N-acetyl-l-cysteine (NAC), a derivative of the naturally occurring
amino acid l-cysteine, is a mucolytic agent that may also act as an antioxidant by providing …